[go: up one dir, main page]

MX2018014130A - Procedimiento e intermedios para la 6,7-alfa-epoxidacion de 4,6-dienos esteroideos. - Google Patents

Procedimiento e intermedios para la 6,7-alfa-epoxidacion de 4,6-dienos esteroideos.

Info

Publication number
MX2018014130A
MX2018014130A MX2018014130A MX2018014130A MX2018014130A MX 2018014130 A MX2018014130 A MX 2018014130A MX 2018014130 A MX2018014130 A MX 2018014130A MX 2018014130 A MX2018014130 A MX 2018014130A MX 2018014130 A MX2018014130 A MX 2018014130A
Authority
MX
Mexico
Prior art keywords
epoxidation
dienses
alfa
steroid
intermediates
Prior art date
Application number
MX2018014130A
Other languages
English (en)
Other versions
MX378594B (es
Inventor
Evans Timothy
Komsta Zofia
WALLIS Laura
Charles Weymouth-Wilson Alexander
Original Assignee
Nzp Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nzp Uk Ltd filed Critical Nzp Uk Ltd
Publication of MX2018014130A publication Critical patent/MX2018014130A/es
Publication of MX378594B publication Critical patent/MX378594B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/001—Oxiranes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • C07J41/0061—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives one of the carbon atoms being part of an amide group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0088—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing unsubstituted amino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
    • C07J13/007—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 17 (20)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Toxicology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invención se relaciona con un procedimiento para preparar un compuesto de formula general (Ia): (ver formula) (Ia) en donde R2, Y, R4 y R5 son como se definen en la presente, en donde la epoxidacion se lleva a cabo usando un oxidante y metiltrioxorenio como catalizador (MeReO3); la invención también se relaciona con ciertos compuestos per se; los compuestos son intermedios en la síntesis de ácidos biliares 10 sintéticos.
MX2018014130A 2016-05-18 2017-05-18 Procedimiento e intermedios para la 6,7-alfa-epoxidacion de 4,6-dienos esteroideos MX378594B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1608776.9A GB201608776D0 (en) 2016-05-18 2016-05-18 Methods and compounds
PCT/GB2017/051389 WO2017199036A1 (en) 2016-05-18 2017-05-18 Process and intermediates for the 6,7-alpha-epoxidation of steroid 4,6-dienes

Publications (2)

Publication Number Publication Date
MX2018014130A true MX2018014130A (es) 2019-04-29
MX378594B MX378594B (es) 2025-03-11

Family

ID=56320628

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018014130A MX378594B (es) 2016-05-18 2017-05-18 Procedimiento e intermedios para la 6,7-alfa-epoxidacion de 4,6-dienos esteroideos

Country Status (14)

Country Link
US (1) US10766921B2 (es)
EP (1) EP3458467B1 (es)
JP (1) JP7034094B2 (es)
KR (1) KR102489565B1 (es)
CN (1) CN109415404B (es)
AU (1) AU2017265445B2 (es)
CA (1) CA3024283C (es)
DK (1) DK3458467T3 (es)
EA (1) EA038224B1 (es)
ES (1) ES2841324T3 (es)
GB (1) GB201608776D0 (es)
MX (1) MX378594B (es)
PT (1) PT3458467T (es)
WO (1) WO2017199036A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201608777D0 (en) 2016-05-18 2016-06-29 Dextra Lab Ltd Compounds
GB201608776D0 (en) 2016-05-18 2016-06-29 Dextra Lab Ltd Methods and compounds
GB201812382D0 (en) 2018-07-30 2018-09-12 Nzp Uk Ltd Compounds
CN111560045A (zh) * 2020-06-23 2020-08-21 江苏佳尔科药业集团股份有限公司 一种以ba为原料合成石胆酸的方法
CN114957371B (zh) * 2021-09-08 2023-10-31 湖南醇康医药科技有限公司 地屈孕酮及其中间体化合物的制备方法
CN114957372B (zh) * 2021-12-07 2023-10-31 湖南醇康医药科技有限公司 10α-甲基-5,7-二烯甾体化合物和地屈孕酮的制备方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2624748A (en) 1950-09-09 1953-01-06 Upjohn Co Bisnorchola-4, 6-dien-3-one-22-al
IT1088094B (it) 1976-10-14 1985-06-04 Hoffmann La Roche Derivati del pregnano
US4289872A (en) 1979-04-06 1981-09-15 Allied Corporation Macromolecular highly branched homogeneous compound based on lysine units
US5229490A (en) 1987-05-06 1993-07-20 The Rockefeller University Multiple antigen peptide system
DE3902357A1 (de) 1989-01-27 1990-08-02 Hoechst Ag Verwendung von rheniumorganischen verbindungen zur oxidation von c-c-mehrfachbindungen, darauf basierende oxidationsverfahren und neue rheniumorganische verbindungen
US5166372A (en) 1992-02-07 1992-11-24 Arco Chemical Technology, L.P. Epoxidation process
JPH07505915A (ja) 1992-04-14 1995-06-29 コーネル　リサーチ　ファウンデーション、インコーポレーテッド 樹枝状巨大分子およびその製造法
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5723636A (en) 1996-04-12 1998-03-03 National Starch And Chemical Investment Holding Corporation Methyltrioxorhenium-urea hydrogen peroxide epoxidation of olefins
JP4021327B2 (ja) 2001-03-12 2007-12-12 インターセプト ファーマスーティカル インコーポレイテッド Ｆｘｒに対する作用薬としてのステロイド
US20090062256A1 (en) 2001-06-01 2009-03-05 Bristol-Myers Squibb Pharma Company LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF Abeta PROTEIN PRODUCTION
US7026440B2 (en) 2001-11-07 2006-04-11 Nektar Therapeutics Al, Corporation Branched polymers and their conjugates
ITMI20030352A1 (it) 2003-02-27 2004-08-28 Chemi Spa Metodo per la sintesi di metiltriossorenio.
EP1568706A1 (en) 2004-02-26 2005-08-31 Intercept Pharmaceuticals, Inc. Novel steroid agonist for FXR
KR20070067078A (ko) 2004-07-13 2007-06-27 미쓰비시 가가꾸 가부시키가이샤 스테로이드 화합물의 제조 방법
ITMI20050912A1 (it) * 2005-05-19 2006-11-20 Erregierre Spa Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici
JP2007210888A (ja) 2006-01-12 2007-08-23 Mitsubishi Chemicals Corp ステロイド化合物の製造方法
ES2523591T3 (es) 2006-06-27 2014-11-27 Intercept Pharmaceuticals Inc. Derivados de ácidos biliares como ligandos de FXR para la prevención o el tratamiento de enfermedades o estados mediados por FXR
US8796249B2 (en) 2008-07-30 2014-08-05 Intercept Pharmaceuticals, Inc. TGR5 modulators and methods of use thereof
CN106380502A (zh) 2008-11-19 2017-02-08 英特塞普特医药品公司 G蛋白偶联受体5(tgr5)调节剂及其使用方法
CA2769203A1 (en) 2009-07-29 2011-02-03 University Of Chicago Liver x receptor agonists
EP3789394A1 (en) 2012-06-19 2021-03-10 Intercept Pharmaceuticals, Inc. Crystalline forms c of obeticholic acid
CA2889592A1 (en) 2012-10-26 2014-05-01 Roberto Pellicciari Process for preparing bile acid derivatives
BR112015012312A2 (pt) 2012-11-28 2017-07-11 Intercept Pharmaceuticals Inc método de tratamento, redução do risco, prevenção ou alívio de uma afecção ou doença pulmonar em um sujeito; método de redução ou supressão de inflamação no pulmão em um sujeito; e método de promoção de reparo pulmonar em um sujeito
US20140206657A1 (en) 2013-01-18 2014-07-24 City Of Hope Bile acid analog tgr5 agonists
WO2015183794A1 (en) 2014-05-27 2015-12-03 City Of Hope Tgr5 agonist complexes for treating diabetes and cancer
EP3221334B1 (en) 2014-11-19 2020-02-19 Nzp Uk Limited 6.alpha.-alkyl-6,7-dione steroids as intermediates for the production of steroidal fxr modulators
US10538550B2 (en) 2014-11-19 2020-01-21 NZP UK Limited 6.alpha.-alkyl-3,7-dione steroids as intermediates for the production of steroidal FXR modulators
EA033445B1 (ru) 2014-11-19 2019-10-31 Nzp Uk Ltd 5-бета-6-алкил-7-гидрокси-3-оновые стероиды в качестве промежуточных соединений для получения стероидных модуляторов fxr
CA2968309A1 (en) * 2014-11-19 2016-05-26 NZP UK Limited 6-alkyl-7-hydroxy-4-en-3-one steroids as intermediates for the production of steroidal fxr modulators
US11578097B2 (en) 2014-11-26 2023-02-14 Enanta Pharmaceuticals, Inc. Tetrazole derivatives of bile acids as FXR/TGR5 agonists and methods of use thereof
CN105348365A (zh) 2014-12-03 2016-02-24 四川百利药业有限责任公司 一种胆酸衍生物及其制备方法、药物组合物和用途
GB201608776D0 (en) 2016-05-18 2016-06-29 Dextra Lab Ltd Methods and compounds
GB201608779D0 (en) * 2016-05-18 2016-06-29 Dextra Lab Ltd Methods and compounds
GB201608777D0 (en) 2016-05-18 2016-06-29 Dextra Lab Ltd Compounds

Also Published As

Publication number Publication date
EP3458467A1 (en) 2019-03-27
KR20190007011A (ko) 2019-01-21
EP3458467B1 (en) 2020-09-30
WO2017199036A1 (en) 2017-11-23
GB201608776D0 (en) 2016-06-29
BR112018073492A2 (pt) 2019-03-26
MX378594B (es) 2025-03-11
JP7034094B2 (ja) 2022-03-11
AU2017265445B2 (en) 2020-12-03
JP2019516729A (ja) 2019-06-20
US10766921B2 (en) 2020-09-08
PT3458467T (pt) 2021-01-05
DK3458467T3 (da) 2020-12-14
CA3024283A1 (en) 2017-11-23
CN109415404B (zh) 2022-08-26
EA201892516A1 (ru) 2019-05-31
US20190309012A1 (en) 2019-10-10
ES2841324T3 (es) 2021-07-08
CN109415404A (zh) 2019-03-01
EA038224B1 (ru) 2021-07-27
AU2017265445A1 (en) 2018-11-15
CA3024283C (en) 2024-07-02
KR102489565B1 (ko) 2023-01-17

Similar Documents

Publication Publication Date Title
MX2018014130A (es) Procedimiento e intermedios para la 6,7-alfa-epoxidacion de 4,6-dienos esteroideos.
MX2018014128A (es) 6.7.beta-epoxidos esteroideos como intermedios quimicos.
MX350892B (es) Síntesis de compuesto antiviral.
HN2011000341A (es) Compuestos derivados de sulfonamidas, composiciones farmaceuticos y proceso de preparacion de los mismos
MX2019012815A (es) Proceso para la preparacion de compuestos de 2,3-dihidrotiazolo[3, 2-a]pirimidin-4-io opticamente activo.
NZ726356A (en) Processes for preparing antiviral compounds
AR116790A1 (es) PROCEDIMIENTO PARA LA PREPARACIÓN DE 3a-HIDROXI-5a-PREGNAN-20-ONA (BREXANOLONA)
CO7141403A2 (es) Procesos para producir ciertos 2 (piridin 3 il)tiazoles
MX2020010330A (es) Proceso para preparar un compuesto antiviral de formula i.
MY199318A (en) Process for preparing chiral 2,3-dihydrothiazolo[3,2-a]pyrimidin-4-ium compounds
BR112016029333A2 (pt) síntese de compostos de carbamoilpiridona policíclico
CL2020001589A1 (es) Proceso para la preparación de derivados de quinolina.
MX2017006565A (es) Esteroides 6.alfa.-alquil-3,7-diona como intermedios para la produccion de moduladores esteroides del receptor x farnesoide (fxr).
MX2017006567A (es) Esteroides 6.alfa.-alquil-6,7-diona como intermedios para la produccion de moduladores esteroides del receptor x farnesoide (fxr).
MX2017006563A (es) Esteroides de 6-alquil-7-hidroxi-4-en-3-ona como intermedios para la produccion de moduladores esteroides del receptor x farnesoide (fxr).
EA201691031A1 (ru) Синтез макроциклического трипептида, ингибирующего hcv ns3
BR112019025028A2 (pt) Método para preparar um composto.
CL2020001049A1 (es) Proceso para producir compuestos de piridazinona herbicida.
MX2017001459A (es) Sintesis de fosforamidatos.
WO2015120111A3 (en) Expedient synthesis of sitagliptin
BR112012013582A2 (pt) processo para síntese de intermediários úteis para a produção de compostos de indazol e azaindazol substituídos
CO7141402A2 (es) Procesos para producir ciertos 2 (piridin 3 il)tiazoles
MX2020001431A (es) Proceso para preparar un enol eter biciclico.
MX2020009462A (es) Procesos para la preparación de compuestos de pirimidinilciclopentano.
UY35766A (es) Proceso industrial para la síntesis de ingredientes activos esteroides